Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 5, 1996, Pages 687-694

  Corsini, A ^a   Bonfatti, M ^a   Quarato, P ^a   Accomazzo, M R ^a   Raiteri, M ^a   Sartani, A ^b   Testa, R ^b   Nicosia, S ^a   Paoletti, R ^a   Fumagalli, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Recordati SpA   (Italy)

Author keywords

Atherosclerosis; Calcium antagonists; Cytosolic calcium; Fluo 3; L Type channels; Lercanidipine; Smooth muscle cells

Indexed keywords

CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; LERCANIDIPINE;

ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; MALE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AORTA; BRAIN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; NITRENDIPINE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 10544246073     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199611000-00012     Document Type: Article

References (49)

1. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1991;91(suppl 1B):1B-3S-1B-9S.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
3. Katsuda S, Boyd HC, Fligner C, Ross R, Gown AM. Human atherosclerosis. III. Immunocytochemical analysis of the cell composition of lesions of young adults. Am J Pathol 1992;140:907-14.
4. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986;58:427-44.
5. Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle: a multifactorial mesenchymal cell. Arch Pathol Lab Med 1988;112:977-86.
6. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;15:1667-87.
7. Clowes AW, Clowes MM, Fingerle J. Regulation of smooth muscle cell growth injured artery. J Cardiovasc Pharmacol 1989;14:S12-5.
8. Wissler RW. Vesselinovitch D, Komatsu A. The contribution of studies of atherosclerotic lesions in young people to future research. Ann N Y Acad Sci 1990;598:418-34.
9. Schmitz G, Hankovitz J, Kovacs EM. Cellular processes in atherogenesis: potential targets of calcium channel blockers. Atherosclerosis 1991;88:109-32.
10. Nakao J, Ito H, Ooyama T, Chang W-C, Murota S. Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid: effects of A23187, nicardipine and trifluoperazine. Atherosclerosis 1983;46:309-19.
11. Corsini A, Quarato P, Raiteri M, et al. Effect of nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res 1993;27:299-307.
12. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension 1992;20:713-36.
13. Waters D, Lesperance J. Interventions that beneficially influence the evolution of coronary atherosclerosis: the case for calcium channel blockers. Circulation 1992;86(suppl III): 111-6.
14. Parmley WW. Vascular protection from atherosclerosis: potential of calcium antagonists. Am J Cardiol 1990;66:161-221.
15. Bianchi G, Leonardi A. Rec 15/2375. Drugs Future 1987;12:1113-6.
16. Guarneri L, Angelico P, Ibba M, et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneim Forschung/Drug Res 1996;46:15-24.
17. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971;50:172-86.
18. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.
19. Skalli O, Ropraz P, Trezciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against alfa-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103:2787-96.
20. Corsini A, Verri D, Raiteri M, Quarato P, Paoletti R, Fumagalli R. Effect of 26-aminocholesterol, 27-hydroxycholesterol and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol 1995;15:420-8.
21. Nakao J, Ooyama T, Ito H, Chang W-C, Murota S. Comparative effect of lipoxygenase products of arachidonic acid on rat aortic smooth muscle cell migration. Atherosclerosis 1982;44:339-42.
22. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F. Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis 1990;83:9-14.
23. Elmore E, Swift M. Growth of cultured cells from patients with Fanconi anemia. J Cell Physiol 1976;87:229-34.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
25. Minta A, Kao JPY, Tsun RY. Fluorescent indicators for cytosolic calcium based on rhodamine and fluoroscein chromophores. J Biol Chem 1989;264:8171-8.
26. 2+ in platelets and neutrophils. Biochem J 1990;269:513-9.
27. Tsien RY, Pozzan T, Rink TJ. Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator. J Cell Biol 1982;94:325-34.
28. De Lean A, Munson P, Rodbard J. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978;235:E97-102.
29. Fisher RA, Yates F. Statistical tables for biological, agricultural and medical research. 4th ed. Edinburgh: Oliver & Boyd, 1953:60.
30. Bernini F, Corsini A, Raiteri M, Soma MR, Paoletti R. Effects of lacidipine on experimental models of atherosclerosis. J Hypertens 1993;11(suppl l):S61-6.
31. Corsini A, Raiteri M, Dimitri V, et al. Vascular smooth muscle and atherosclerosis: role of isoprenoids and calcium antagonists. J Vasc Med Biol 1994;5:111-9.
32. Bernini F, Corsini A, Bellosta S, Fumagalli R. Effect of lacidipine, nifedipine, and verapamil on cellular processes of atherogenesis [Abstract]. Pharmacol Res 1992;26(suppl 1):29.
33. Jackson CL, Bush RC, Bowyer DE. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 1989;80:17-26.
34. Henry PD. Calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol 1990;16:S12-5.
35. Bernini F, Catapano AL, Corsini A, Fumagalli R, Paoletti R. Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol 1989;64:1291-331.
36. Lichtlen PT. Hugenholtz PG, Rafflenbleu W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-13.
37. Waters D, Lespérance J, Francetich M, et al. A controlled clinical trial to assess the effect of calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.
38. Nayler WG, Britnell S. Calcium antagonists and tissue protection. J Cardiovasc Pharmacol 1991;18:S1-5.
39. Rampe D, Caffrey JM, Schneider MD, Brown AM. Control of expression of the 1,4-dihydropyridine receptor in BC3H1 cells. Biochem Biophys Res Commun 1988;152:769-75.
40. Kruse H-J, Bauriedel G, Heimerl J, Hotting B, Weber PC. Role of L-type calcium channels on stimulated calcium influx and on proliferative activity of human coronary smooth muscle cells. J Cardiovasc Pharmacol 1994;24:328-35.
41. 2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts. Am J Physiol 1993:265:C1239-46.
42. Schmitt R, Clozel JP, Iberg N, Buhler FR. Mibefradil prevents neointima formation after vascular injury in rats: possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 1995;15:1161-5.
43. Sironi G, Rinoldi O, Greto L, Testa R. Effects of lercanidipine (L) and its enantiomers on systemic haemodynamics and on ventricular relaxation in chronically instrumented conscious dogs [Abstract]. J Mol Cell Cardiol 1995;27:A386.
44. Graziani F, Ratti E, van Amesterdam FTM. Interaction of lacidipine with its receptor binding site supports a slow onset and long duration of action. J Cardiovasc Pharmacol 1996;27:290-6.
45. Jackson CL, Bush RC, Bowyer DE. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis 1988;69:115-22.
46. O'Brien ER, Alpers CE, Stewart DK, et al. Proliferation in primary and restenotic coronary atherectomy tissue: implication for antiproliferative therapy. Circ Res 1993;73:223-31.
47. Katsuda S, Coltrera MD, Ross R, Gown AM. Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol 1993;142:1787-93.
48. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993;91:1469-80.
49. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990;87:4600-4.